{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:30:15Z","timestamp":1788993015948,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T00:00:00Z","timestamp":1649635200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001713","name":"European and Developing Countries Clinical Trials Partnership","doi-asserted-by":"publisher","award":["TMA2018CDF-2351"],"award-info":[{"award-number":["TMA2018CDF-2351"]}],"id":[{"id":"10.13039\/501100001713","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH-NURTURE","award":["D43TW010132"],"award-info":[{"award-number":["D43TW010132"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Second-line drug resistance (SLD) among tuberculosis (TB) patients is a serious emerging challenge towards global control of the disease.\u00a0We characterized SLD-resistance conferring-mutations among TB patients with rifampicin and\/or isoniazid (RIF and\/or INH) drug-resistance tested at the Uganda National TB Reference Laboratory (NTRL) between June 2017 and December 2019.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This was a descriptive cross-sectional secondary data analysis\u00a0of 20,508 M<jats:italic>. tuberculosis<\/jats:italic>\u00a0isolates of new and previously treated patients\u2019 resistant to RIF and\/or INH. DNA strips with valid results to characterise the SLD resistance using the commercial Line Probe Assay Genotype\u00a0<jats:italic>MTBDRsl<\/jats:italic>\u00a0Version 2.0 Assay (Hain Life Science, Nehren, Germany) were reviewed. Data were analysed with STATAv15 using cross-tabulation for frequency and proportions of known resistance-conferring mutations to injectable agents (IA) and fluoroquinolones (FQ).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Among the eligible participants, 12,993\/20,508 (63.4%) were male and median (IQR) age 32 (24\u201343). A total of 576\/20,508 (2.8%) of the <jats:italic>M. tuberculosis<\/jats:italic>\u00a0isolates from participants had resistance to RIF and\/or INH. These included; 102\/576 (17.7%) single drug-resistant and 474\/576 (82.3%) multidrug-resistant (MDR) strains. Only 102 patients had test results for FQ of whom 70\/102 (68.6%) and 01\/102 (0.98%) had resistance-conferring mutations in the <jats:italic>gyrA<\/jats:italic>\u00a0locus and <jats:italic>gyrB<\/jats:italic>\u00a0locus respectively. Among patients with FQ resistance, <jats:italic>gyrAD94G<\/jats:italic> 42.6% (30.0\u201355.9) and <jats:italic>gyrA A90V<\/jats:italic> 41.1% (28.6\u201354.3) mutations were most observed. Only one mutation, E540D was detected in the\u00a0<jats:italic>gyrB<\/jats:italic>\u00a0locus. A total of 26 patients had resistance-conferring mutations to IA in whom, 20\/26 77.0% (56.4\u201391.0) had A1401G mutation in the\u00a0<jats:italic>rrs<\/jats:italic>\u00a0gene locus.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our study reveals a high proportion of mutations known to confer high-level fluoroquinolone drug-resistance among patients with rifampicin and\/or isoniazid drug resistance. Utilizing routinely generated laboratory data from existing molecular diagnostic methods may aid real-time surveillance of emerging tuberculosis drug-resistance in resource-limited settings.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-022-07339-w","type":"journal-article","created":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T12:04:12Z","timestamp":1649678652000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Molecular characterisation of second-line drug resistance among drug resistant tuberculosis patients tested in Uganda: a two and a half-year\u2019s review"],"prefix":"10.1186","volume":"22","author":[{"given":"Dennis","family":"Mujuni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianah Linda","family":"Kasemire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Ibanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Kabugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Nsawotebba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jody E.","family":"Phelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Kaos","family":"Majwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didas","family":"Tugumisirize","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdunoor","family":"Nyombi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Orena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Turyahabwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Byabajungu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Nadunga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Musisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moses Lutakoome","family":"Joloba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1643-110X","authenticated-orcid":false,"given":"Willy","family":"Ssengooba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,11]]},"reference":[{"key":"7339_CR1","unstructured":"World Health Organisation. Global TB Report 2018. 2018. https:\/\/apps.who.int\/iris\/handle\/10665\/274453. Accessed 3 Feb 2021."},{"key":"7339_CR2","unstructured":"World Health Organisation. Global TB Report 2019. https:\/\/apps.who.int\/iris\/handle\/10665\/274453. Accessed 3 Feb 2021."},{"key":"7339_CR3","unstructured":"TB Report - Apps on Google Play. https:\/\/play.google.com\/store\/apps\/details?id=uk.co.adappt.whotbreport&hl=en_US&gl=UG. Accessed 4 Jul 2021."},{"key":"7339_CR4","unstructured":"World Health Organisation. Global TB Report 2020. https:\/\/www.who.int\/publications\/i\/item\/9789240013131. Accessed 3 Nov 2021."},{"key":"7339_CR5","unstructured":"USAID. Uganda Tuberculosis Roadmap Overview, Fiscal Year 2021. 2020. https:\/\/www.usaid.gov\/sites\/default\/files\/documents\/Uganda_TBRM21_TB_DIAH_Version_Final.pdf. Accessed 3 Nov 2021."},{"key":"7339_CR6","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/2154240","author":"N Awoke","year":"2019","unstructured":"Awoke N, Dulo B, Wudneh F. Total Delay in Treatment of Tuberculosis and Associated Factors among New Pulmonary TB Patients in Selected Health Facilities of Gedeo Zone, Southern Ethiopia, 2017\/18. Interdiscip Perspect Infect Dis. 2019. https:\/\/doi.org\/10.1155\/2019\/2154240.","journal-title":"Interdiscip Perspect Infect Dis"},{"key":"7339_CR7","volume-title":"Major infectious diseases","author":"BR Bloom","year":"2017","unstructured":"Bloom BR, Atun R, Cohen T, Dye C, Fraser H, Gomez GB, et al. Tuberculosis. In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors., et al., Major infectious diseases. 3rd ed. Washington: The International Bank for Reconstruction and Development\/The World Bank; 2017.","edition":"3"},{"key":"7339_CR8","unstructured":"Truenat TB Test - Diagnosis, resistance testing, COVID-19\u2014TBFacts. https:\/\/tbfacts.org\/truenat\/. Accessed 4 Jul 2021."},{"key":"7339_CR9","unstructured":"Global Laboratory Initiative. Global Laboratory Initiative Line probe assays for drug- resistant tuberculosis detection. 2008. -. https:\/\/stoptb.org\/wg\/gli\/assets\/documents\/LPA_test_web_ready.pdf. Accessed 2 Nov 2021."},{"key":"7339_CR10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2007.01711.x","author":"MY Lipin","year":"2007","unstructured":"Lipin MY, Stepanshina VN, Shemyakin IG, Shinnick TM. Association of specific mutations in {katG}, {rpoB}, rps L and rrs genes with spoligotypes of multidrug-resistant Mycobacterium tuberculosis isolates in Russia. Clin Microbiol Infect. 2007. https:\/\/doi.org\/10.1111\/j.1469-0691.2007.01711.x.","journal-title":"Clin Microbiol Infect"},{"key":"7339_CR11","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ910","author":"JP Cegielski","year":"2016","unstructured":"Cegielski JP, Kurbatova E, Walt MVD, Brand J, Ershova J, Tupasi T, et al. Multidrug-resistant tuberculosis treatment outcomes in relation to treatment and initial versus acquired second-line drug resistance. Clin Infect Dis. 2016. https:\/\/doi.org\/10.1093\/cid\/civ910.","journal-title":"Clin Infect Dis"},{"key":"7339_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12879-016-1487-1","volume":"16","author":"GW Kasule","year":"2016","unstructured":"Kasule GW, Kateete DP, Joloba ML. Mycobacterium tuberculosis Uganda II is more susceptible to rifampicin and isoniazid compared to Beijing and Delhi\/CAS families. BMC Infect Dis. 2016;16:1\u20138.","journal-title":"BMC Infect Dis"},{"key":"7339_CR13","unstructured":"Siddiqi SH, R\u00fcsch-Gerdes S. For BACTEC MGIT 960 TB system. 2006. https:\/\/www.finddx.org\/wp-content\/uploads\/2016\/02\/mgit_manual_nov2006.pdf. Accessed 3 Nov 2021."},{"key":"7339_CR14","unstructured":"GenoLyse\u00ae | Manual isolation of bacterial DNA from patient samples. https:\/\/www.hain-lifescience.de\/produkte\/dna-isolierung\/genolyse.html. Accessed 20 Nov 2021."},{"key":"7339_CR15","unstructured":"International Standards Organisation. ISO - ISO 15189:2012 - Medical laboratories \u2014 Requirements for quality and competence. 3rd Edition. https:\/\/www.iso.org\/standard\/56115.html. Accessed 3 Feb 2021."},{"key":"7339_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-019-0891-x","author":"DP Kateete","year":"2019","unstructured":"Kateete DP, Kamulegeya R, Kigozi E, Katabazi FA, Lukoye D, Sebit SI, et al. Frequency and patterns of second-line resistance conferring mutations among MDR-TB isolates resistant to a second-line drug from eSwatini, Somalia and Uganda (2014\u20132016). BMC Pulm Med. 2019. https:\/\/doi.org\/10.1186\/s12890-019-0891-x.","journal-title":"BMC Pulm Med"},{"key":"7339_CR17","doi-asserted-by":"publisher","first-page":"220","DOI":"10.2991\/j.jegh.2018.02.100","volume":"8","author":"R Yadav","year":"2018","unstructured":"Yadav R, Saini A, Mankotia J, Khaneja R, Agarwal P, Sethi S. Genetic characterization of second-line drug-resistant and extensively drug-resistant mycobacterium tuberculosis from the Northern Region of India. J Epidemiol Glob Health. 2018;8:220\u20134.","journal-title":"J Epidemiol Glob Health"},{"key":"7339_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens8040208","author":"T Mogashoa","year":"2019","unstructured":"Mogashoa T, Melamu P, Derendinger B, Ley SD, Kgwaadira B, Rankgoane-pono G, et al. Detection of Second line drug resistance among drug resistant Mycobacterium tuberculosis isolates. Pathogens. 2019. https:\/\/doi.org\/10.3390\/pathogens8040208.","journal-title":"Pathogens"},{"key":"7339_CR19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2471\/BLT.11.092585","volume":"90","author":"M Zignol","year":"2012","unstructured":"Zignol M, van Gemert W, Falzon D, Sismanidis C, Glaziou P, Floyd K, et al. Surveillance of anti-tuberculosis drug resistance in the world: an updated analysis, 2007\u20132010. Bull World Health Organ. 2012;90:111\u20139.","journal-title":"Bull World Health Organ"},{"key":"7339_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12889-015-1376-3","volume":"15","author":"BJ Kirenga","year":"2015","unstructured":"Kirenga BJ, Ssengooba W, Muwonge C, Nakiyingi L, Kyaligonza S, Kasozi S, et al. Tuberculosis risk factors among tuberculosis patients in Kampala, Uganda: implications for tuberculosis control. BMC Public Health. 2015;15:13.","journal-title":"BMC Public Health"},{"key":"7339_CR21","first-page":"271","volume":"23","author":"A Berhan","year":"2013","unstructured":"Berhan A, Berhan Y, Yizengaw D. A meta-analysis of drug resistant tuberculosis in sub-saharan africa: how strongly associated with previous treatment and HIV co-infection? Ethiop J Health Sci. 2013;23:271\u201382.","journal-title":"Ethiop J Health Sci"},{"key":"7339_CR22","unstructured":"World Health Organisation. Global Tuberculosis Report 2017. https:\/\/www.who.int\/tb\/publications\/global_report\/gtbr2017_main_text.pdf. Accessed 3 Feb 2021."},{"issue":"Suppl 2","key":"7339_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/infdis\/jiw035","volume":"213","author":"M Joloba","year":"2016","unstructured":"Joloba M, Mwangi C, Alexander H, Nadunga D, Bwanga F, Modi N, et al. Strengthening the tuberculosis specimen referral network in Uganda: the role of public-private partnerships. J Infect Dis. 2016;213(Suppl 2):41\u20136.","journal-title":"J Infect Dis"},{"key":"7339_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab018","author":"JH Malenfant","year":"2021","unstructured":"Malenfant JH, Brewer TF. Rifampicin mono-resistant tuberculosis\u2014a review of an uncommon but growing challenge for global tuberculosis control. Open Forum Infect Dis. 2021. https:\/\/doi.org\/10.1093\/ofid\/ofab018.","journal-title":"Open Forum Infect Dis"},{"key":"7339_CR25","doi-asserted-by":"publisher","first-page":"e0259221","DOI":"10.1371\/journal.pone.0259221","volume":"16","author":"LN Micheni","year":"2021","unstructured":"Micheni LN, Kassaza K, Kinyi H, Ntulume I, Bazira J. Rifampicin and isoniazid drug resistance among patients diagnosed with pulmonary tuberculosis in southwestern Uganda. PLoS ONE. 2021;16:e0259221.","journal-title":"PLoS ONE"},{"key":"7339_CR26","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.meegid.2016.02.019","volume":"40","author":"W Ssengooba","year":"2016","unstructured":"Ssengooba W, Meehan CJ, Lukoye D, William G, Musisi K, Joloba ML, et al. Infection, genetics and evolution whole genome sequencing to complement tuberculosis drug resistance surveys in Uganda. Infect Genet Evol. 2016;40:8\u201316.","journal-title":"Infect Genet Evol"},{"key":"7339_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010705.pub3.www.cochranelibrary.com","author":"G Theron","year":"2016","unstructured":"Theron G, Peter J, Richardson M, Warren R, Dheda K, Kr S. GenoType\u00ae MTBDRsl assay for resistance to second-line antituberculosis drugs. Cochrane Database Syst Rev. 2016. https:\/\/doi.org\/10.1002\/14651858.CD010705.pub3.www.cochranelibrary.com.","journal-title":"Cochrane Database Syst Rev"},{"key":"7339_CR28","doi-asserted-by":"publisher","first-page":"13991","DOI":"10.1073\/pnas.94.25.13991","volume":"94","author":"X Zhao","year":"1997","unstructured":"Zhao X, Xu C, Domagala J, Drlica K. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc Natl Acad Sci USA. 1997;94:13991\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7339_CR29","doi-asserted-by":"publisher","first-page":"3994","DOI":"10.1128\/AAC.00222-16","volume":"60","author":"SB Georghiou","year":"2016","unstructured":"Georghiou SB, Seifert M, Catanzaro D, Garfein RS, Valafar F, Crudu V, et al. Frequency and distribution of tuberculosis resistance-associated mutations between Mumbai, Moldova, and Eastern Cape. Antimicrob Agents Chemother. 2016;60:3994\u20134004.","journal-title":"Antimicrob Agents Chemother"},{"key":"7339_CR30","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.2147\/IDR.S289907","volume":"14","author":"S Cheng","year":"2021","unstructured":"Cheng S, Hide M, Pheng SH, Kerl\u00e9guer A, Delvallez G, Sam S, et al. Resistance to second-line anti-TB drugs in cambodia: a phenotypic and genetic study. IDR. 2021;14:1089\u2013104.","journal-title":"IDR"},{"key":"7339_CR31","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1128\/AAC.00851-09","volume":"53","author":"L Jugheli","year":"2009","unstructured":"Jugheli L, Bzekalava N, de Rijk P, Fissette K, Portaels F, Rigouts L. High level of cross-resistance between kanamycin, amikacin, and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene. Antimicrob Agents Chemother. 2009;53:5064\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"7339_CR32","doi-asserted-by":"publisher","first-page":"20004","DOI":"10.1073\/pnas.0907925106","volume":"106","author":"MA Zaunbrecher","year":"2009","unstructured":"Zaunbrecher MA, Sikes RD, Metchock B, Shinnick TM, Posey JE. Overexpression of the chromosomally encoded aminoglycoside acetyltransferase eis confers kanamycin resistance in Mycobacterium tuberculosis. PNAS. 2009;106:20004\u20139.","journal-title":"PNAS"},{"key":"7339_CR33","doi-asserted-by":"publisher","first-page":"9804","DOI":"10.1073\/pnas.1105379108","volume":"108","author":"W Chen","year":"2011","unstructured":"Chen W, Biswas T, Porter VR, Tsodikov OV, Garneau-Tsodikova S. Unusual regioversatility of acetyltransferase Eis, a cause of drug resistance in XDR-TB. PNAS. 2011;108:9804\u20138.","journal-title":"PNAS"},{"key":"7339_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijmyco.2015.09.001","volume":"5","author":"P Kambli","year":"2016","unstructured":"Kambli P, Ajbani K, Nikam C, Sadani M, Shetty A, Udwadia Z, et al. Correlating RRS and EIS promoter mutations in clinical isolates of Mycobacterium tuberculosis with phenotypic susceptibility levels to the second-line injectables. Int J Mycobacteriol. 2016;5:1\u20136.","journal-title":"Int J Mycobacteriol"},{"key":"7339_CR35","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1111\/jam.14478","volume":"128","author":"R Singh","year":"2020","unstructured":"Singh R, Dwivedi SP, Gaharwar US, Meena R, Rajamani P, Prasad T. Recent updates on drug resistance in Mycobacterium tuberculosis. J Appl Microbiol. 2020;128:1547\u201367.","journal-title":"J Appl Microbiol"},{"key":"7339_CR36","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/1471-2180-14-165","volume":"14","author":"A Sowajassatakul","year":"2014","unstructured":"Sowajassatakul A, Prammananan T, Chaiprasert A, Phunpruch S. Molecular characterization of amikacin, kanamycin and capreomycin resistance in M\/XDR-TB strains isolated in Thailand. BMC Microbiol. 2014;14:165.","journal-title":"BMC Microbiol"},{"key":"7339_CR37","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12941-018-0285-6","volume":"17","author":"A Sowajassatakul","year":"2018","unstructured":"Sowajassatakul A, Prammananan T, Chaiprasert A, Phunpruch S. Overexpression of eis without a mutation in promoter region of amikacin- and kanamycin-resistant Mycobacterium tuberculosis clinical strain. Ann Clin Microbiol Antimicrob. 2018;17:33.","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"7339_CR38","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/S0140-6736(12)60734-X","volume":"380","author":"T Dalton","year":"2012","unstructured":"Dalton T, Cegielski P, Akksilp S, Asencios L, Caoili JC, Cho S, et al. Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries\u202f: a prospective cohort study. Lancet. 2012;380:1406\u201317.","journal-title":"Lancet"},{"key":"7339_CR39","doi-asserted-by":"crossref","unstructured":"Almeida Da Silva PEA, Palomino JC. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J Antimicrob Chemother. 2011;66:1417\u201330.","DOI":"10.1093\/jac\/dkr173"},{"key":"7339_CR40","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1183\/09031936.00061808","volume":"32","author":"DI Ling","year":"2008","unstructured":"Ling DI, Zwerling AA, Pai M. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J. 2008;32:1165\u201374.","journal-title":"Eur Respir J"},{"key":"7339_CR41","doi-asserted-by":"publisher","first-page":"e88626","DOI":"10.1371\/journal.pone.0088626","volume":"9","author":"N Raizada","year":"2014","unstructured":"Raizada N, Sachdeva KS, Chauhan DS, Malhotra B, Reddy K, Dave PV, et al. A multi-site validation in india of the line probe assay for the rapid diagnosis of multi-drug resistant tuberculosis directly from sputum specimens. PLoS ONE. 2014;9:e88626.","journal-title":"PLoS ONE"},{"key":"7339_CR42","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02169-16","author":"A Ajileye","year":"2017","unstructured":"Ajileye A, Alvarez N, Merker M, Walker TM, Akter S, Brown K, et al. Some synonymous and nonsynonymous gyra mutations in mycobacterium tuberculosis lead to systematic false-positive fluoroquinolone resistance results with the hain GenoType MTBDRsl assays. Antimicrob Agents Chemother. 2017. https:\/\/doi.org\/10.1128\/AAC.02169-16.","journal-title":"Antimicrob Agents Chemother"},{"key":"7339_CR43","unstructured":"WHO announces updated definitions of extensively drug-resistant tuberculosis. https:\/\/www.who.int\/news\/item\/27-01-2021-who-announces-updated-definitions-of-extensively-drug-resistant-tuberculosis. Accessed 23 Jul 2021."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07339-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-022-07339-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-022-07339-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T12:07:54Z","timestamp":1649678874000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-022-07339-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,11]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["7339"],"URL":"https:\/\/doi.org\/10.1186\/s12879-022-07339-w","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,11]]},"assertion":[{"value":"11 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data used in this study was initially collected for routine care in efforts to detect and control the spread of tuberculosis. Administrative approval to access the routinely collected de-identified laboratory data was obtained from the National TB reference Laboratory, National TB Program\u2014Ministry of Health, Kampala, Uganda. A confidentiality agreement signed by the author and filed with the Data Manager. All the data collected for the study were fully anonymized and no patient names were used throughout the data collection and analysis phase. No additional approval was required since the study utilized de-identified routinely collected data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"363"}}